Trials / Not Yet Recruiting
Not Yet RecruitingNCT07459283
The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors
Evaluation of the Safety, Dosimetry and Efficacy of 177Lu-INN805 Injection in Patients With Malignant Solid Tumors
- Status
- Not Yet Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- FindCure Biosciences (ZhongShan) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a prospective, single-arm, open-label, dose-escalation study. A total of 4 dose groups were pre-defined in this study. The drug was administered once every 6 weeks.The drug would be administered for 1 to 4 cycles. The dosing schedule and dose could also be adjusted according to the patient's condition. After each dose group completed the enrollment and DLT observation, based on the participant's safety tolerance, radiation dosimetry, and preliminary efficacy evaluation results, it was decided whether to adjust the dose of the subsequent dose groups or to suspend the dose escalation.
Conditions
- Maligant Solid Tumor
- Head & Neck Cancer
- Thyroid Cancer
- Lung Cancer - Non Small Cell Squamous
- Breast Cancer
- Sarcoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INN805 | The drug was administered once every 6 weeks. It was expected that the drug would be administered for 1 to 4 cycles. |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2026-12-01
- Completion
- 2027-03-01
- First posted
- 2026-03-09
- Last updated
- 2026-03-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07459283. Inclusion in this directory is not an endorsement.